Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis (DATA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Benjamin Leder, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00926380
First received: June 19, 2009
Last updated: November 30, 2016
Last verified: November 2016